Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Rev Neurol. 2010;6(3):131–44.

Article  CAS  Google Scholar 

Blennow K. A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood. Neurol Therapy. 2017;6(Suppl 1):15–24.

Article  Google Scholar 

Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimer’s Res Therapy. 2015;7:74.

Article  Google Scholar 

Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain. 2015;138(Pt 11):3373–85.

Article  PubMed  PubMed Central  Google Scholar 

Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimer’s Dementia. 2015;11(10):1180–90.

Article  PubMed  Google Scholar 

Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372–84.

Article  CAS  PubMed  Google Scholar 

Tarawneh R, D’Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol. 2016;73(5):561–71.

Article  PubMed  PubMed Central  Google Scholar 

Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res. 2010;1362:13–22.

Article  CAS  PubMed  Google Scholar 

Skillback T, Mattsson N, Blennow K, Zetterberg H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5-6):397–403.

Article  PubMed  Google Scholar 

Zetterberg H. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. Neuron. 2016;91(1):1–3.

Article  CAS  PubMed  Google Scholar 

Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights. 2020;15:1177271920950319.

Article  PubMed  PubMed Central  Google Scholar 

Kern S, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Waern M, et al. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA neurology. 2018. https://doi.org/10.1001/jamaneurol.2018.3459.

Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Simrén J, Geiger F, et al. Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. Alzheimer’s Dementia. 2022;14(1):e12295.

PubMed Central  Google Scholar 

Rydberg Sterner T, Ahlner F, Blennow K, Dahlin-Ivanoff S, Falk H, Havstam Johansson L, et al. The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. Eur J Epidemiol. 2018. https://doi.org/10.1007/s10654-018-0459-8.

Kern S, Zetterberg H, Kern J, Zettergren A, Waern M, Hoglund K, et al. Prevalence of preclinical Alzheimer disease: Comparison of current classification systems. Neurology. 2018;90(19):e1682–e91.

Article  PubMed  PubMed Central  Google Scholar 

Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. 1993;43(11):2412--a.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Vemuri P, et al. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimer’s Dementia. 2019;15(11):1437–47.

Article  PubMed  Google Scholar 

Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. New England J Med. 1993;328(3):153–8.

Article  CAS  Google Scholar 

Kern J, Kern S, Blennow K, Zetterberg H, Waern M, Guo X, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology. 2016;87(16):1674–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). 1987.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282–9.

Article  PubMed  Google Scholar 

Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Letters. 2000;285(1):49–52.

Article  CAS  Google Scholar 

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231–45.

Article  CAS  PubMed  Google Scholar 

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673–80.

Article  CAS  PubMed  Google Scholar 

Gaetani L, Hoglund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer’s Res Therapy. 2018;10(1):8.

Article  Google Scholar 

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoglund K, Kern S, Zettergren A, Borjesson-Hansson A, Zetterberg H, Skoog I, et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry. 2017;7(1):e995.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–34.

Article  CAS  PubMed  Google Scholar 

Rådestig MA, Skoog J, Zetterberg H, Skillbäck T, Zettergren A, Sterner TR, et al. Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study. J Alzheimers Dis. 2023;91(1):291–303. https://doi.org/10.3233/JAD-220452.

Rådestig MA, Skoog J, Zetterberg H, Kern J, Zettergren A, Sacuiu S, et al. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer’s Disease: Results from the Gothenburg H70 Birth Cohort Studies. J Alzheimer’s Dis. 2021;79(1):225–35.

Article  Google Scholar 

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.

Article  CAS  PubMed  Google Scholar 

Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017;74(5):557–66.

Article  PubMed  PubMed Central  Google Scholar 

Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica. 2018;136(3):363–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jadhav S, Cubinkova V, Zimova I, Brezovakova V, Madari A, Cigankova V, et al. Tau-mediated synaptic damage in Alzheimer’s disease. Transl Neurosci. 2015;6(1):214–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164–78.

Article  CAS  PubMed  Google Scholar 

Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathologica. 2016;131(1):27–48.

Article  CAS  PubMed  Google Scholar 

Pooler AM, Noble W, Hanger DP. A role for tau at the synapse in Alzheimer’s disease pathogenesis. Neuropharmacol. 2014;76 Pt A:1-8.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95(11):6448–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferreira ST, Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Memory. 2011;96(4):529–43.

Article  CAS  Google Scholar 

Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24(45):10191–200.

Article  CAS  PubMed  PubMed Central